Bold claim: HPV vaccines dramatically cut cervical cancer risk and raise almost no serious safety concerns, especially when given before exposure to the virus. And this is exactly what two new Cochrane reviews from UK researchers reveal, offering the most robust and consistent evidence to date. They show vaccination in early adolescence not only prevents cancer and high-grade precancerous lesions, but also does not increase the risk of major adverse events.
Scope and strength of the evidence
- The reviews combine data from randomized controlled trials (RCTs) and large population studies, encompassing more than 132 million people. This breadth provides a powerful picture of real-world impact.
- One population-level analysis covering 225 studies across 46 countries found an 80% reduction in cervical cancer among girls vaccinated by age 16 (risk ratio 0.20). Vaccination given later in adolescence or adulthood showed smaller risk reductions, underscoring the advantage of early immunization.
- The same work also indicates moderate-certainty evidence that HPV vaccination lowers rates of precancerous cervical lesions and reduces the occurrence of anogenital warts.
- Importantly, the studies found no evidence connecting HPV vaccination to infertility, chronic fatigue syndrome, Guillain–Barré syndrome, or complex regional pain syndrome.
RCT-focused findings
- A separate synthesis of RCTs evaluated four WHO-approved vaccines—Cervarix, Gardasil, Gardasil-9, and Cecolin—across 60 trials with 157,414 participants. Although trials couldn’t take long enough to observe cancer outcomes, vaccines reduced high-grade vaccine-matched precancerous cervical lesions by 60% (risk ratio 0.40) among females aged 15–25 over six years.
- Across 39 studies, rates of serious adverse events did not differ between vaccine and control groups (risk ratio 0.99) over up to 72 months of follow-up.
Geographic and research gaps
- While the findings are the most comprehensive to date, gaps remain. Much of the research comes from high-income countries, highlighting the need for more studies in lower- and middle-income nations where cervical cancer screening may be less accessible. Longer-term studies are also needed to fully capture the durability of protection and the impact on other cancers linked to HPV, such as vulvar, peri-anal, penile, and head-and-neck cancers, which tend to manifest later in life.
Implications and next steps
- The evidence supports prioritizing early adolescent HPV vaccination as a key cancer-prevention strategy. Policymakers and health systems should focus on increasing coverage before age 16 to maximize population benefits.
- Researchers should aim to fill geographic gaps with long-term follow-up to quantify lifetime protection and to monitor any rare adverse events beyond the current observation windows.
Author perspective
According to senior author Jo Morrison, longer-term data will strengthen understanding of how HPV vaccination protects against cancer across a lifetime. While current data already demonstrate a beneficial effect on cervical cancer—an outcome that typically arises in younger populations—the full picture, including effects on other HPV-related cancers, will emerge over decades.
